Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.44 |
| ▸ | PDE1A | P54750 | 4/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.44 |
| ▸ | PDE9A | O76083 | 9/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688890 | 0.92 | KDM4E (0.45) | GRM1TP53MAPTKDM4EPDE1C | |
| SCHEMBL1753303 | 0.92 | GRM1 (0.45) | GRM1TP53MAPTKDM4EPDE1C | |
| SCHEMBL1753242 | 0.92 | PDE1C (0.55) | GRM1TP53MAPTKDM4EPDE1C | |
| SCHEMBL1753228 | 0.81 | TP53 (0.53) | GRM1TP53MAPTKDM4E | |
| SCHEMBL1753239 | 0.81 | GRM1 (0.69) | GRM1TP53MAPTKDM4E | |
| SCHEMBL1753382 | 0.79 | TP53 (0.51) | GRM1TP53MAPTKDM4EPDE1C | |
| SCHEMBL1688983 | 0.78 | ALDH1A1 (0.40) | GRM1TP53MAPTKDM4E | |
| SCHEMBL1753563 | 0.77 | TP53 (0.58) | GRM1TP53MAPTKDM4E | |
| SCHEMBL1753264 | 0.77 | TP53 (0.47) | GRM1TP53MAPTKDM4E | |
| SCHEMBL1753235 | 0.77 | TP53 (0.62) | GRM1TP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | claimed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | claimed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | GRM1 69/4885TP53 4640/4885MAPT 1780/4885 |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | GRM1 69/4885TP53 4640/4885MAPT 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.